Salivary Gland Cancer is an indication for drug development with over 50 pipeline drugs currently active. According to GlobalData, preregistered drugs for Salivary Gland Cancer have a 100% likelihood of approval (LoA) indication benchmark. GlobalData’s report assesses how phase transition success rate (PTSR) and likelihood of approval (LoA) scores for pipeline drugs in Salivary Gland Cancer compared to historical benchmarks. Buy the report here.

Smarter leaders trust GlobalData

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

Salivary Gland Cancer overview

Salivary gland cancer refers to malignant tumors that develop in the tissues of the salivary glands, which produce saliva to aid in digestion and maintain oral health. These glands are located in various areas of the mouth and throat, including the parotid glands (the largest salivary glands), submandibular glands, sublingual glands, and numerous minor glands throughout the mouth. Salivary gland cancers can be classified into different types based on the specific cells they originate from, including mucoepidermoid carcinoma, adenoid cystic carcinoma, acinic cell carcinoma, and adenocarcinoma.

For a complete picture of PTSR and LoA scores for drugs in Salivary Gland Cancer, buy the report here.

Data Insights


The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article. 

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.